Christophe Ferme

Summary

Affiliation: Institut Gustave Roussy
Country: France

Publications

  1. ncbi request reprint Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease
    Christophe Ferme
    Department of Medicine, Institut de Cancerologie Gustave Roussy, Villejuif, France
    N Engl J Med 357:1916-27. 2007
  2. ncbi request reprint A weekly regimen with dose escalation of doxorubicin for patients with advanced Hodgkin's lymphoma: results of a phase II study of the Groupe d'Etudes des Lymphomes de l'Adulte (GELA)
    Christophe Ferme
    Department of Medicine, Institut de Cancerologie Gustave Roussy, Villejuif, France
    Leuk Lymphoma 48:691-8. 2007
  3. doi request reprint Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA)
    Vincent Ribrag
    Hematology Department, Gustave Roussy Institute, Villejuif, France
    Cancer 115:4540-6. 2009
  4. ncbi request reprint Hodgkin's disease primarily involving the oropharynx: case report and review of the literature
    Samir Aloulou
    Service d Hematologie, Institut Gustave Roussy, Villejuif, France
    Hematol J 3:164-7. 2002
  5. ncbi request reprint Role of FDG-PET in the Implementation of Involved-Node Radiation Therapy for Hodgkin Lymphoma Patients
    Theodore Girinsky
    Department of Radiotherapy, Institut Gustave Roussy, Villejuif, France
    Int J Radiat Oncol Biol Phys 89:1047-52. 2014
  6. pmc Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin's lymphoma
    Vincent Ribrag
    Institut de Cancerologie Gustave Roussy, Villejuif, France
    Haematologica 98:357-63. 2013
  7. ncbi request reprint Prospective study of bone marrow infiltration in aggressive lymphoma by three independent methods: whole-body MRI, PET/CT and bone marrow biopsy
    Vincent Ribrag
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Eur J Radiol 66:325-31. 2008
  8. ncbi request reprint Long-term results and competing risk analysis of the H89 trial in patients with advanced-stage Hodgkin lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte (GELA)
    Christophe Ferme
    Departement of Medecine, Institut Gustave Roussy, 39 Rue C Desmoulins, 94805 Villejuif Cedex, France
    Blood 107:4636-42. 2006
  9. ncbi request reprint Phase II study of concomitant chemoradiotherapy in bulky refractory or chemoresistant relapsed lymphomas
    Theodore Girinsky
    Department of Radiation Oncology, Institut Gustave Roussy, Villejuif 94805, France
    Int J Radiat Oncol Biol Phys 61:476-9. 2005
  10. ncbi request reprint Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial
    Christophe Ferme
    Groupe d Etudes des Lymphomes de l Adulte, Hopital Saint Louis, Paris, France
    J Clin Oncol 20:467-75. 2002

Detail Information

Publications13

  1. ncbi request reprint Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease
    Christophe Ferme
    Department of Medicine, Institut de Cancerologie Gustave Roussy, Villejuif, France
    N Engl J Med 357:1916-27. 2007
    ..Treatment of early-stage Hodgkin's disease is usually tailored in line with prognostic factors that allow for reductions in the amount of chemotherapy and extent of radiotherapy required for a possible cure...
  2. ncbi request reprint A weekly regimen with dose escalation of doxorubicin for patients with advanced Hodgkin's lymphoma: results of a phase II study of the Groupe d'Etudes des Lymphomes de l'Adulte (GELA)
    Christophe Ferme
    Department of Medicine, Institut de Cancerologie Gustave Roussy, Villejuif, France
    Leuk Lymphoma 48:691-8. 2007
    ..The relapse rate was related to the short duration of chemotherapy, and the failure to prevent relapses with consolidation RT. In this study population the 16-week regimen and RT to bulky sites were not sufficient for disease control...
  3. doi request reprint Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA)
    Vincent Ribrag
    Hematology Department, Gustave Roussy Institute, Villejuif, France
    Cancer 115:4540-6. 2009
    ..The authors conducted a randomized phase 2 trial of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with the addition of bortezomib in patients with B-cell lymphoma...
  4. ncbi request reprint Hodgkin's disease primarily involving the oropharynx: case report and review of the literature
    Samir Aloulou
    Service d Hematologie, Institut Gustave Roussy, Villejuif, France
    Hematol J 3:164-7. 2002
    ..This report is followed by a discussion on the clinical and pathological features, the implication of Epstein-Barrs virus and a literature review for Hodgkin's disease involving Waldeyer's ring...
  5. ncbi request reprint Role of FDG-PET in the Implementation of Involved-Node Radiation Therapy for Hodgkin Lymphoma Patients
    Theodore Girinsky
    Department of Radiotherapy, Institut Gustave Roussy, Villejuif, France
    Int J Radiat Oncol Biol Phys 89:1047-52. 2014
    ....
  6. pmc Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin's lymphoma
    Vincent Ribrag
    Institut de Cancerologie Gustave Roussy, Villejuif, France
    Haematologica 98:357-63. 2013
    ..Combinations of plitidepsin with other chemotherapeutic drugs deserve further evaluation in patients with non-cutaneous peripheral T-cell lymphoma. (clinicaltrials.gov identifier: NCT00884286)...
  7. ncbi request reprint Prospective study of bone marrow infiltration in aggressive lymphoma by three independent methods: whole-body MRI, PET/CT and bone marrow biopsy
    Vincent Ribrag
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Eur J Radiol 66:325-31. 2008
    ..The aim of this study was to compare the performance of BMB, whole-body MRI and PET/CT for evaluation of BM infiltration...
  8. ncbi request reprint Long-term results and competing risk analysis of the H89 trial in patients with advanced-stage Hodgkin lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte (GELA)
    Christophe Ferme
    Departement of Medecine, Institut Gustave Roussy, 39 Rue C Desmoulins, 94805 Villejuif Cedex, France
    Blood 107:4636-42. 2006
    ..An analysis of competing risks identified age more than 45 years as a significant risk factor for death, relapse, and second cancers. Prospective evaluation of late adverse events may improve the management of patients with HL...
  9. ncbi request reprint Phase II study of concomitant chemoradiotherapy in bulky refractory or chemoresistant relapsed lymphomas
    Theodore Girinsky
    Department of Radiation Oncology, Institut Gustave Roussy, Villejuif 94805, France
    Int J Radiat Oncol Biol Phys 61:476-9. 2005
    ..To evaluate the local efficacy of concomitant chemoradiotherapy in patients with mostly refractory lymphoma...
  10. ncbi request reprint Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial
    Christophe Ferme
    Groupe d Etudes des Lymphomes de l Adulte, Hopital Saint Louis, Paris, France
    J Clin Oncol 20:467-75. 2002
    ....
  11. pmc Role of imaging to choose treatment
    Christophe Ferme
    Department of Medicine, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
    Cancer Imaging 5:S113-9. 2005
    ..The WHO criteria are the only ones used to evaluate treatment results on CT, even though the use of PET is increasingly used, with better and better results...
  12. doi request reprint Low-dose radiation treatment in pulmonary mucosa-associated lymphoid tissue lymphoma: a plausible approach? A single-institution experience in 10 patients
    Theodore Girinsky
    Department of Radiation Oncology, Institut Gustave Roussy, Villejuif, France
    Int J Radiat Oncol Biol Phys 83:e385-9. 2012
    ..To propose an alternative approach for treatment of pulmonary marginal zone lymphoma, using a very small radiation dose (2 × 2 Gy) delivered exclusively to tumor sites...
  13. pmc Management of fertility in patients treated for Hodgkin's lymphoma
    Stephanie Harel
    Service d immuno hématologie, Hopital Saint Louis, Paris, France
    Haematologica 96:1692-9. 2011
    ..The risk of secondary infertility should be discussed with patients from the time of the diagnosis and requires multidisciplinary collaboration between hematologists and Assisted Reproductive Techniques (ART) teams...